CY1119947T1 - Φαρμακοτεχνικη μορφη αναισθητικου φαρμακου - Google Patents
Φαρμακοτεχνικη μορφη αναισθητικου φαρμακουInfo
- Publication number
- CY1119947T1 CY1119947T1 CY20171101164T CY171101164T CY1119947T1 CY 1119947 T1 CY1119947 T1 CY 1119947T1 CY 20171101164 T CY20171101164 T CY 20171101164T CY 171101164 T CY171101164 T CY 171101164T CY 1119947 T1 CY1119947 T1 CY 1119947T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical form
- anesthetic agents
- neuroactive steroid
- anesthetic medicine
- cyclodextrins
- Prior art date
Links
- 230000003444 anaesthetic effect Effects 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 3
- 239000003193 general anesthetic agent Substances 0.000 abstract 3
- 229940097362 cyclodextrins Drugs 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- 229940035674 anesthetics Drugs 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- -1 sulfoalkyl ether Chemical compound 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29724910P | 2010-01-21 | 2010-01-21 | |
| US38531810P | 2010-09-22 | 2010-09-22 | |
| PCT/AU2011/000050 WO2011088503A1 (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119947T1 true CY1119947T1 (el) | 2018-12-12 |
Family
ID=44306295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101164T CY1119947T1 (el) | 2010-01-21 | 2017-11-07 | Φαρμακοτεχνικη μορφη αναισθητικου φαρμακου |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8697678B2 (enExample) |
| EP (1) | EP2525798B1 (enExample) |
| JP (1) | JP5930311B2 (enExample) |
| KR (1) | KR101747476B1 (enExample) |
| CN (1) | CN102802635B (enExample) |
| AU (1) | AU2011207103B2 (enExample) |
| BR (1) | BR112012017800B1 (enExample) |
| CA (1) | CA2786762C (enExample) |
| CL (1) | CL2012002032A1 (enExample) |
| CY (1) | CY1119947T1 (enExample) |
| DK (1) | DK2525798T3 (enExample) |
| ES (1) | ES2646829T3 (enExample) |
| GB (2) | GB2491491B (enExample) |
| HR (1) | HRP20171699T1 (enExample) |
| HU (1) | HUE035441T2 (enExample) |
| LT (1) | LT2525798T (enExample) |
| NO (1) | NO2525798T3 (enExample) |
| NZ (1) | NZ601255A (enExample) |
| PL (1) | PL2525798T3 (enExample) |
| PT (1) | PT2525798T (enExample) |
| RS (1) | RS56576B1 (enExample) |
| RU (1) | RU2574022C2 (enExample) |
| SG (1) | SG181997A1 (enExample) |
| SI (1) | SI2525798T1 (enExample) |
| SM (1) | SMT201700518T1 (enExample) |
| WO (1) | WO2011088503A1 (enExample) |
| ZA (1) | ZA201205370B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| JP5819005B2 (ja) * | 2011-11-29 | 2015-11-18 | ジュロックス プロプライエタリー リミテッド | 薬学的組成物 |
| NZ627781A (en) * | 2012-01-23 | 2016-10-28 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| SG10201608148TA (en) * | 2012-08-21 | 2016-11-29 | Sage Therapeutics Inc | Methods Of Treating Epilepsy Or Status Epilepticus |
| EP2916846B1 (en) * | 2012-11-09 | 2025-09-17 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| ES2973320T3 (es) | 2012-11-30 | 2024-06-19 | Univ California | Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto |
| WO2015134670A1 (en) * | 2014-03-05 | 2015-09-11 | Mingbao Zhang | Deuterated ganaxolone derivatives |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016127170A1 (en) * | 2015-02-06 | 2016-08-11 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| WO2017066626A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| TW202400182A (zh) | 2016-03-08 | 2024-01-01 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及用途 |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2019202640A1 (ja) | 2018-04-16 | 2019-10-24 | 川崎重工業株式会社 | ベルトコンベヤ |
| JP7443358B2 (ja) * | 2018-07-03 | 2024-03-05 | ドローブリッジ ファーマシューティカルズ ピーティーワイ リミテッド | 神経活性ステロイドおよび調製の方法 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| JP2022514991A (ja) * | 2018-12-10 | 2022-02-16 | ハロー・サイエンス・エル・エル・シー | 安定な麻酔薬製剤および関連する剤形 |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| CN114828889B (zh) | 2019-12-06 | 2025-02-14 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69006259T2 (de) * | 1989-05-24 | 1994-06-09 | Innovet Inc | Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung. |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993017711A1 (en) * | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| JP4227675B2 (ja) * | 1996-10-25 | 2009-02-18 | 康武 日地 | 神経毒軽減麻酔剤 |
| AUPQ633900A0 (en) * | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CA2441744C (en) * | 2001-03-20 | 2011-07-12 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| CN101583620B (zh) * | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
-
2011
- 2011-01-19 KR KR1020127021761A patent/KR101747476B1/ko active Active
- 2011-01-19 JP JP2012549208A patent/JP5930311B2/ja active Active
- 2011-01-19 SI SI201131342T patent/SI2525798T1/en unknown
- 2011-01-19 BR BR112012017800-8A patent/BR112012017800B1/pt not_active IP Right Cessation
- 2011-01-19 HR HRP20171699TT patent/HRP20171699T1/hr unknown
- 2011-01-19 EP EP11734245.1A patent/EP2525798B1/en active Active
- 2011-01-19 AU AU2011207103A patent/AU2011207103B2/en active Active
- 2011-01-19 PT PT117342451T patent/PT2525798T/pt unknown
- 2011-01-19 NZ NZ601255A patent/NZ601255A/xx not_active IP Right Cessation
- 2011-01-19 RS RS20171135A patent/RS56576B1/sr unknown
- 2011-01-19 US US13/574,201 patent/US8697678B2/en active Active
- 2011-01-19 LT LTEP11734245.1T patent/LT2525798T/lt unknown
- 2011-01-19 SM SM20170518T patent/SMT201700518T1/it unknown
- 2011-01-19 RU RU2012134321/15A patent/RU2574022C2/ru active
- 2011-01-19 GB GB1210657.1A patent/GB2491491B/en active Active
- 2011-01-19 ES ES11734245.1T patent/ES2646829T3/es active Active
- 2011-01-19 HU HUE11734245A patent/HUE035441T2/en unknown
- 2011-01-19 WO PCT/AU2011/000050 patent/WO2011088503A1/en not_active Ceased
- 2011-01-19 DK DK11734245.1T patent/DK2525798T3/da active
- 2011-01-19 CN CN201180013975.2A patent/CN102802635B/zh not_active Expired - Fee Related
- 2011-01-19 CA CA2786762A patent/CA2786762C/en active Active
- 2011-01-19 PL PL11734245T patent/PL2525798T3/pl unknown
- 2011-01-19 SG SG2012050159A patent/SG181997A1/en unknown
- 2011-01-19 NO NO11734245A patent/NO2525798T3/no unknown
- 2011-01-19 GB GB1201842.0A patent/GB2484244B/en active Active
-
2012
- 2012-07-18 ZA ZA2012/05370A patent/ZA201205370B/en unknown
- 2012-07-20 CL CL2012002032A patent/CL2012002032A1/es unknown
-
2013
- 2013-11-01 US US14/069,751 patent/US8975245B2/en active Active
-
2017
- 2017-11-07 CY CY20171101164T patent/CY1119947T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119947T1 (el) | Φαρμακοτεχνικη μορφη αναισθητικου φαρμακου | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| CY1124690T1 (el) | Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη | |
| CY1122732T1 (el) | Συνθεσεις για αναπνευστικη χορηγηση δραστικων παραγοντων και συναφεις μεθοδοι και συστηματα | |
| CY1123485T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια νοσων | |
| CY1121373T1 (el) | Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| CY1125263T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa | |
| CY1122687T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| CY1113315T1 (el) | Ιμιδαζολοκαρβοξαμιδια | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| CY1119897T1 (el) | Προφαρμακο αδρενομεδουλλινης βασιζομενο σε πολυαιθυλενογλυκολη και χρηση αυτου | |
| CY1121910T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση | |
| MX2013013942A (es) | Proteinas de union abcma (cd269/tnfrsf17). | |
| EP2464224A4 (en) | METHOD FOR THE ADMINISTRATIVE ADMINISTRATION WITH UNFOLDED AND FOLDED PROTEINS AND PEPTID NANOPARTICLES | |
| MX379365B (es) | Conjugados y partículas direccionados y formulaciones de estos. | |
| CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
| CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
| CY1119184T1 (el) | Κυκλικες ν,ν’-διαρυλοθειουριες και ν,ν’-διαρυλουριες ως ανταγωνιστες υποδοχεων ανδρογονων, αντι-καρκινικος παραγοντας, μεθοδος για παραγωγη και χρηση τους | |
| CO7160008A2 (es) | Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| JOP20190263A1 (ar) | عوامل RNAi لتثبيط التعبير عن Alpha- EnaC وطرق استخدامها | |
| CY1118528T1 (el) | Φαρμακευτικες συνθεσεις για τη θεραπεια καταθλιψης και αγχους |